Search

everythinglearnresearchcommunity

for

Search:↓

No single ideal JAK inhibitor for alopecia areata has been determined; JAK3 inhibitors may be promising with fewer side effects.

Janus Kinase inhibitors are effective and have an acceptable safety profile for treating moderate to severe Ulcerative Colitis.

Tofacitinib and adalimumab are promising treatments for cicatricial alopecia with few side effects.

Certain HSD3B1 gene types are linked to worse prostate cancer outcomes and affect treatment response and other health conditions.

Tofacitinib, a hair regrowth treatment, may worsen acne.

Baricitinib effectively improved both atopic dermatitis and alopecia areata symptoms in a patient.

Upadacitinib improved hair regrowth and quality of life in alopecia areata patients with minimal side effects.

Upadacitinib may help treat difficult cases of systemic lupus erythematosus.

Upadacitinib significantly improved alopecia universalis and psoriatic arthritis in a patient.

Ivacaftor can protect against noise-induced hearing loss by reducing oxidative stress.

Upadacitinib and oral minoxidil improved Crohn's disease and hair regrowth in a patient.

A JAK inhibitor improved both severe hair loss and chronic skin disease in one patient.

A substance called sodium zinc dihydrolipoylhistidinate can significantly reduce hair loss caused by chemotherapy in rats.

Blocking CCR5 can prevent and improve hair loss in alopecia areata.

JAK inhibitors help treat some diseases but may increase risks of blood clots and cancer in certain patients.

Baricitinib helped a woman with severe hair loss regrow almost all her hair without side effects.

JAK inhibitors effectively treat severe alopecia areata with manageable side effects.

A mix of specific inhibitors and a growth factor helps keep hair growth cells from losing their properties in the lab.

A woman developed lupus after taking hydroxyurea for two years.

Upadacitinib effectively treated a patient with multiple inflammatory conditions.

GMG-43AC may help reduce unwanted hair growth and treat certain hair loss conditions.

34% of patients on hepatitis C treatment had reversible skin issues.

Betulinic acid can help treat hepatitis C by stopping virus replication.

Baricitinib reduces inflammation and mitochondrial damage in skin cells.

Ritlecitinib effectively reduces hair loss in JAK inhibitor-naïve alopecia areata patients.

Farudodstat may help prevent hair loss in alopecia areata by stopping immune attacks on hair follicles.

Baricitinib was effective in treating a patient with dermatomyositis and hair loss.

Tofacitinib improved ulcerative colitis, skin ulcers, and hair loss in a patient who didn't respond well to other treatments.